Appointment of Director of Medical Physics

RNS Number : 0031J

Advanced Oncotherapy PLC

06 September 2016

 

6 September 2016

Advanced Oncotherapy plc

("Advanced Oncotherapy" or the "Company")

Appointment of International Director of Medical Physics

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that it has appointed Richard Amos as International Director of Medical Physics, a non-board position, with effect from 1 November 2016.

Richard joins Advanced Oncotherapy from University College London Hospitals NHS Trust, where he was Operational Lead for Proton Therapy Physics at the Department of Radiotherapy Physics. He is also an honorary senior lecturer at the Department of Medical Physics and Biomedical Engineering at University College London. He was a Senior Medical Physicist at The University of Texas MD Anderson Cancer Center in Houston, and was Medical Physicist in the Department of Radiation Medicine in the proton centre at Loma Linda University Medical Center in California. In 2016, the MD Anderson Cancer Center was ranked No. 1 for cancer treatment in the US.  The James M Slater Proton Treatment and Research Center at Loma Linda was the first hospital based US proton treatment centre in the world. Today the centre uses proton beam technology for many types of cancers and has treated more patients than any other proton treatment centre worldwide.

Richard is highly regarded in his field and has had 19 peer-reviewed journal articles published. He has also had 74 abstracts printed and is a regular reviewer and editor of medical journals. He holds a BSc (Hons) in Applied Physics from the University of Coventry and an MSc in Applied Radiation Physics from the University of Birmingham, where he was awarded the European Social Fund Graduate Scholarship.

Commenting, Richard Amos said: "My main research interests centre on the clinical implementation of Proton Beam Therapy ('PBT'), with a major focus being on developing treatment planning techniques to treat the current UK indication list for PBT and to investigate the potential of PBT for other indications, particularly left-sided breast cancer. I am also interested in investigating methods of optimising PBT plan robustness and minimising uncertainties associated with proton beam delivery. The development of novel imaging techniques to monitor and verify proton dose delivery in vivo is one of my main areas of expertise. The technical advantages of AVO'S LIGHT Accelerator promise unique opportunities to enhance the precision and adaptive characteristics of PBT."

The company further announces that it has today issued 29,542 new ordinary shares ("New Ordinary Shares") of 25p in the Company at a subscription price of 135.4 pence per Ordinary Share (being the average closing price over the last three months) to an employee as part of their remuneration package.

Application has been made for the 29,542 Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will occur on or about 9 September 2016. The Shares will rank pari passu in all aspects with the existing ordinary shares of the Company.

Total voting rights

Following Admission, the Company's enlarged issued share capital will comprise 58,809,903 ordinary shares, with voting rights. The Company does not hold any ordinary shares in treasury. Therefore, the total number of ordinary shares in the Company with voting rights will be 58,809,903. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

For further information, please contact:

Advanced Oncotherapy plc	www.avoplc.com
Michael Sinclair, Chief Executive Officer	Tel: [phone]
Nicolas Serandour, Chief Operating and Financial Officer
Stockdale Securities (Nomad & Joint Broker)
Antonio Bossi / David Coaten	Tel: [phone]
Beaufort Securities (Joint Broker)
Jon Belliss / Elliot Hance	Tel: [phone]
Walbrook PR (Financial PR & IR)	Tel: [phone] or [e-mail]
Paul McManus	Mob: [phone]
Anna Dunphy	Mob: [phone]

About Advanced Oncotherapy plc www.avoplc.com

Advanced Oncotherapy is a provider of particle therapy systems with protons that harnesses the best in modern technology. As a result, Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology as well as better health outcomes and lower treatment related side effects.

Advanced Oncotherapy's team "ADAM" based in Geneva focuses on the development of a proprietary proton accelerator called Linac Image Guided Hadron Technology ("LIGHT"). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a unit that is a fraction of the size and significantly lower in cost. This compact configuration delivers proton beams in a way that facilitates a greater precision and electronic control which is not achievable with older technologies.

The Company has signed two purchase agreements with Sinophi Healthcare Limited for the LIGHT proton therapy systems to be installed in hospitals in China. There are also four additional framework agreements and further Letters of Intent from other healthcare providers.

The Company has also signed a joint venture agreement with CircleHealth, owned by AIM-listed Circle Holdings plc, to operate the Company's proton beam cancer therapy centre in Harley Street.

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.

 

END

 

 

MSCAKPDKABKDKCK